Colon cancer survival rates

Adjuvant chemotherapy is administered after tumor resection to decrease relapse rates and improve survival in patients with colon cancer by eliminating micrometastatic disease that is undetected on imaging studies. Patients diagnosed with stage I colon or rectal cancer usually are cured by surgical resection, and adjuvant chemotherapy is not indicated in these patients.16 The role of adjuvant... 

It was significantly effective when used in combination with fluorouracil-based chemotherapy and led to the improvement of overall response rates, time to progression, and survival of patients with metastatic colon cancer (55,57,58). Bevacizumab and irinotecan, fluorouracil, leucov-orin (IFL) chemotherapy regimen showed an increase in median survival by 4.7 months, in progression free survival by 4.36 months, and in overall response rates (complete and partial responses) by 10.2% when compared with IFL plus placebo. 

Turnbull RB, Jr, Kyle K, Watson FR, Spratt J. Cancer of the colon The influence of the no-touch isolation technic on survival rates. Ann Surg 1967 166(3) 42(M127. 

TABLE 127—9. Colon and Rectal Cancer Disease Stage and Survival Rates (SEER Data, 1995-2000)... 

Higher response rates are seen when 5-FU is used in combination with other agents, such as cyclophosphamide and methotrexate (breast cancer), cisplatin (head and neck cancer), and with oxaliplatin or irinotecan in colon cancer. The combination of 5-FU and oxaliplatin or irinotecan has become the standard first-line treatment for patients with metastatic colorectal cancer. The use of 5-FU in combination regimens has improved survival in the adjuvant treatment for breast cancer, and with oxaliplatin and leucovorin, for colorectal cancer. 5-FU also... 

There are over 200 different types of cancer, which can affect nearly any type of body tissue. The most common cancer of them all is nonmelanoma skin cancer with more than i million new cases in the United States each year, which is about half of the total of all diagnosed cancers. In second place is colon cancer with about 100,000 new cases in the United States each year. The deadliest is pancreatic cancer, which has a 1-year survival rate of about 3 percent. One of the main reasons for this low survival rate is because the symptoms of pan -aeatic cancer do not typically appear until the cancer has already reached a later stage. 

MR-guided LITT was performed in 839 patients (mean age 61.6 years) with 2,506 liver metastases of colorectal cancer between 1993 and 2005. The following criteria were analyzed primary tumor and lymph node staging, localization of the primary tumor (rectum, sigmoid, colon), number of liver metastases at first LITT treatment, synchronous (less than 6 months between diagnosis of tumor and first liver metastases) or metachronous metastases, survival rate, and indication for LITT. The Tarone Ware, Breslow, and Log Rank tests were used for statistical significance. 

Apart from its topical use in curing skin cancers, 5-fluorouracil (usually as the ribotide, 5FUdR) is given intravenously to increase the postoperative survival rate in cancer of the colon and rectum (Li and Ross, 1976) and in adenocarcinoma of the breast or colon, and in metastases of the liver (once thought to be inevitably fatal). However, it has yet to be shown that systemic use of this drug can prolong the survival rate beyond 5 years. 

The expression of Pgp, as detected by immunohistochemistry (IHC), has been shown to display a positive correlation with increased relapse rate in osteosarcoma (14). This prognostic significance of Pgp was unrelated to other features of the tumor such as chemotherapy-induced necrosis, which is currently the most important predictor of disease-free survival. It is of interest that in this study the relationship between Pgp and tumor relapse after chemotherapy could not be linked to increased drug efflux from the tumor cells. The chemotherapy used was composed of drugs that are not normally considered to be substrates for Pgp. Therefore, at least in osteosarcoma and perhaps also in colon and breast cancer, the presence of Pgp may not simply be a marker of tumor chemosensi-tivity, but also a sign of tumor aggressiveness (15). 

Fio. 2. Logarithm of percent survival of 130 Scottish patients with untreatable cancer of the colon (after ref. 3), compared with Eq. 1 (straight line) with average rate constant a = 2.58 x 10 (fi/ = 26.9 d). 

---